Literature DB >> 8926282

Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP signals.

M Xia1, S P Sreedharan, E J Goetzl.   

Abstract

An immunoregulatory role for vasoactive intestinal peptide (VIP) is suggested by the high concentrations in subsets of neurons supplying lymphoid organs and by the capacity of VIP to affect T lymphocyte functions. The Tsup-1 line of human T lymphoblastoma cells expresses both type I and type II G protein-coupled VIP receptors (Rs), as shown by detection of the encoding mRNAs with reverse transcription-polymerase chain reaction analyses. Northern blot quantification of the relative amounts of mRNA encoding the two VIPRs in Tsup-1 cells indicated that type II predominates over type I, as it does in human blood CD4+ T cells. Tsup-1 cells bound 125I-VIP to 8.95 x 10(4) high-affinity sites/cell (Kd = 6.0 nM) and 7.45 x 10(5) low-affinity sites/cell (Kd = 210 nM). VIP increased [cAMP]i in Tsup-1 cells (EC50 = 14.4 nM) and stimulated a rapid and transient increase in [Ca2+]i (EC50 = 30 nM). Functional coupling of G proteins to type II VIPRs was suggested by the change in binding of 125I-VIP to Tsup-1 cell membranes from two sites with Kd values of 3.8 and 109 nM to one site of Kd 30 nM by GTP-gamma-S and the suppression by pertussis toxin of increases in [Ca2+]i evoked by VIP. The VIP antagonists, VIP4-28 and (4-Cl-D-Phe6-Leu17) VIP, inhibited 125I-VIP binding by type II VIPRs, as well as VIP-elicited increases in [Ca2+]i and [cAMP]i. Type II VIPRs thus are the major transducers of VIP signals to a subset of human T cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8926282     DOI: 10.1007/bf01540969

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  36 in total

Review 1.  The receptors of the VIP family peptides (VIP, secretin, GRF, PHI, PHM, GIP, glucagon and oxyntomodulin). Specificities and identity.

Authors:  G Rosselin
Journal:  Peptides       Date:  1986       Impact factor: 3.750

2.  Vasoactive intestinal peptide stimulates T lymphocytes to release IL-5 in murine schistosomiasis mansoni infection.

Authors:  R C Mathew; G A Cook; A M Blum; A Metwali; R Felman; J V Weinstock
Journal:  J Immunol       Date:  1992-06-01       Impact factor: 5.422

3.  Receptors for vasoactive intestinal polypeptide on isolated synaptosomes from rat cerebral cortex. Heterogeneity of binding and desensitization of receptors.

Authors:  P Staun-Olsen; B Ottesen; P D Bartels; M H Nielsen; S Gammeltoft; J Fahrenkrug
Journal:  J Neurochem       Date:  1982-11       Impact factor: 5.372

4.  Covalent cross-linking of vasoactive intestinal polypeptide to its receptors on intact human lymphoblasts.

Authors:  C L Wood; M S O'Dorisio
Journal:  J Biol Chem       Date:  1985-01-25       Impact factor: 5.157

5.  Human T-lymphocyte subset specificity of the regulatory effects of leukotriene B4.

Authors:  D G Payan; A Missirian-Bastian; E J Goetzl
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

6.  Distinct patterns of cytoplasmic protein phosphorylation related to regulation of synthesis and release of prolactin by GH cells.

Authors:  A Sobel; A H Tashjian
Journal:  J Biol Chem       Date:  1983-09-10       Impact factor: 5.157

7.  Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.

Authors:  T Ishihara; R Shigemoto; K Mori; K Takahashi; S Nagata
Journal:  Neuron       Date:  1992-04       Impact factor: 17.173

8.  Specific binding sites for vasoactive intestinal polypeptide on nonadherent peripheral blood lymphocytes.

Authors:  A Danek; M S O'Dorisio; T M O'Dorisio; J M George
Journal:  J Immunol       Date:  1983-09       Impact factor: 5.422

9.  Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex.

Authors:  L Sun; D Ganea
Journal:  J Neuroimmunol       Date:  1993-10       Impact factor: 3.478

10.  Pertussis toxin inhibition of chemotactic factor-induced calcium mobilization and function in human polymorphonuclear leukocytes.

Authors:  D W Goldman; F H Chang; L A Gifford; E J Goetzl; H R Bourne
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

View more
  5 in total

1.  Vasoactive intestinal peptide signaling axis in human leukemia.

Authors:  Glenn Paul Dorsam; Keith Benton; Jarrett Failing; Sandeep Batra
Journal:  World J Biol Chem       Date:  2011-06-26

2.  Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors.

Authors:  S A Tannu; L M Renzetti; N Tare; J D Ventre; D Lavelle; T A Lin; A Morschauser; J Paciorek; D R Bolin; H Michel; L Singer; M Hargaden; Id Knowles; P Gardiner; M Cazzola; L Calzetta; M G Matera; A Hicks
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

3.  The neuropeptide VIP potentiates intestinal innate type 2 and type 3 immunity in response to feeding.

Authors:  Maud Pascal; Alexander Kazakov; Gabriel Lepousez; Pierre-Marie Lledo; Christoph Wilhelm; Gérard Eberl; Grégoire Chevalier; Lola Dubrule; Julie Deyrat; Alice Dupin; Soham Saha; Ferdinand Jagot; Kurt Sailor; Sophie Dulauroy; Carine Moigneu; Yasmine Belkaid
Journal:  Mucosal Immunol       Date:  2022-05-02       Impact factor: 8.701

4.  Stimulatory and suppressive signal transduction regulates vasoactive intestinal peptide receptor-1 (VPAC-1) in primary mouse CD4 T cells.

Authors:  Emilie E Vomhof-DeKrey; Glenn Paul Dorsam
Journal:  Brain Behav Immun       Date:  2008-06-13       Impact factor: 7.217

5.  Molecular Mechanisms of Increased Heart Rate in Shenxianshengmai-treated Bradycardia Rabbits.

Authors:  Zhou-Ying Liu; Jian Huang; Na-Na Liu; Min Zheng; Tao Zhao; Bu-Chang Zhao; Yi-Min Wang; Jie-Lin Pu
Journal:  Chin Med J (Engl)       Date:  2017-01-20       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.